Disponibilité de l'information médicale requise pour la déclaration d'une réaction indésirable médicamenteuse à Santé Canada: une étude exploratoire.

The Canadian journal of hospital pharmacy Pub Date : 2024-02-14 eCollection Date: 2024-01-01 DOI:10.4212/cjhp.3489
Laurent Saint-Vil, Thaïna-Rafi Jean-Baptiste, Nicolas Martel-Côté, Denis Lebel, Jean-François Bussières
{"title":"Disponibilité de l'information médicale requise pour la déclaration d'une réaction indésirable médicamenteuse à Santé Canada: une étude exploratoire.","authors":"Laurent Saint-Vil, Thaïna-Rafi Jean-Baptiste, Nicolas Martel-Côté, Denis Lebel, Jean-François Bussières","doi":"10.4212/cjhp.3489","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Since 2019, health care facilities have been required to report serious adverse drug reactions (ADRs) to Health Canada.</p><p><strong>Objectives: </strong>To describe the availability of information required for reporting an ADR to Health Canada from medical records using 2 methods (systematic and in-depth reporting) and to compare the time required to find the information.</p><p><strong>Methods: </strong>This retrospective and prospective descriptive study involved serious ADRs occurring in a mother-child centre and reported between April 1, 2021, and March 31, 2023. The variables needed to complete the Health Canada reporting form were collected using 2 distinct methods.</p><p><strong>Results: </strong>Among the 270 serious ADRs reported retrospectively, 140 were sampled. The average availability of variables was 82.3% (standard deviation [SD] 11.3%), with average data collection time of 50 (SD 25) minutes. For the prospective part of the study, 15 serious ADRs were studied. The availability of variables was 82.8% (SD 6.9%) and 91.9% (SD 7.8%), for systematic and in-depth reporting, respectively, with data collection times of 44 (SD 17) and 130 (SD 33) minutes, respectively.</p><p><strong>Conclusions: </strong>The challenge of finding, in patients' medical records, all of the information needed for reporting an ADR to Health Canada required an in-depth approach. However, the in-depth method took 3 times as long as a search limited to places in the record where specific information should be found. To improve record keeping, additional training for clinicians could be considered and, potentially, development of a computerized clinical record that includes a dedicated form for documenting ADRs.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"77 1","pages":"e3489"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846800/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of hospital pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4212/cjhp.3489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Since 2019, health care facilities have been required to report serious adverse drug reactions (ADRs) to Health Canada.

Objectives: To describe the availability of information required for reporting an ADR to Health Canada from medical records using 2 methods (systematic and in-depth reporting) and to compare the time required to find the information.

Methods: This retrospective and prospective descriptive study involved serious ADRs occurring in a mother-child centre and reported between April 1, 2021, and March 31, 2023. The variables needed to complete the Health Canada reporting form were collected using 2 distinct methods.

Results: Among the 270 serious ADRs reported retrospectively, 140 were sampled. The average availability of variables was 82.3% (standard deviation [SD] 11.3%), with average data collection time of 50 (SD 25) minutes. For the prospective part of the study, 15 serious ADRs were studied. The availability of variables was 82.8% (SD 6.9%) and 91.9% (SD 7.8%), for systematic and in-depth reporting, respectively, with data collection times of 44 (SD 17) and 130 (SD 33) minutes, respectively.

Conclusions: The challenge of finding, in patients' medical records, all of the information needed for reporting an ADR to Health Canada required an in-depth approach. However, the in-depth method took 3 times as long as a search limited to places in the record where specific information should be found. To improve record keeping, additional training for clinicians could be considered and, potentially, development of a computerized clinical record that includes a dedicated form for documenting ADRs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
向加拿大卫生部报告药物不良反应所需医疗信息的可用性:一项探索性研究。
背景:自 2019 年起,医疗机构必须向加拿大卫生部报告严重药物不良反应(ADR):自 2019 年起,医疗机构必须向加拿大卫生部报告严重药物不良反应 (ADR):使用两种方法(系统报告和深入报告)描述从医疗记录中向加拿大卫生部报告 ADR 所需的信息的可用性,并比较查找信息所需的时间:这项回顾性和前瞻性描述性研究涉及 2021 年 4 月 1 日至 2023 年 3 月 31 日期间在母婴中心发生的严重 ADR 报告。采用两种不同的方法收集填写加拿大卫生部报告表所需的变量:在回顾性报告的 270 例严重 ADR 中,抽样调查了 140 例。变量的平均可用率为 82.3%(标准差 [SD] 11.3%),平均数据收集时间为 50 分钟(标准差 25 分钟)。在前瞻性研究中,研究了 15 例严重 ADR。系统报告和深度报告的变量可用率分别为 82.8%(标准差 6.9%)和 91.9%(标准差 7.8%),数据收集时间分别为 44 分钟(标准差 17 分钟)和 130 分钟(标准差 33 分钟):要在患者的医疗记录中找到向加拿大卫生部报告 ADR 所需的全部信息,需要采用深入的方法。然而,深度方法所需的时间是仅限于在病历中找到特定信息的搜索时间的 3 倍。为了改进记录保存,可以考虑对临床医生进行更多培训,并有可能开发一种计算机化的临床记录,其中包括用于记录 ADR 的专用表格。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical Outcomes in Adult Patients Receiving Definitive Cefazolin Therapy for Community-Acquired Enterobacterales Bacteremias across Minimum Inhibitory Concentration Breakpoints. Processus de préparation des cytotoxiques injectables : gestion des risques par l’application de la méthode d’analyse des modes de défaillance, de leurs effets et de leur criticité. Survey of Guidance for Authors on the Use of Generative Artificial Intelligence in Pharmaceutical Journals. Successful Desensitization in a Patient Receiving Pertuzumab and Trastuzumab for ERBB2-Positive Stage IV Breast Cancer: Case Report. Impact of Pharmacist Interventions and Interprofessional Agreement in Critical Care: Analysis Using the Clinical, Economic, and Organizational Tool.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1